中国临床药理学与治疗学
中國臨床藥理學與治療學
중국림상약이학여치료학
CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2002年
4期
320-323
,共4页
沈振宇%丘小汕%陈述枚%李文益%谢衍铭%程少杰%区文玑%袁世珍
瀋振宇%丘小汕%陳述枚%李文益%謝衍銘%程少傑%區文璣%袁世珍
침진우%구소산%진술매%리문익%사연명%정소걸%구문기%원세진
轮状病毒感染%肠炎%免疫球蛋白%血清%猪
輪狀病毒感染%腸炎%免疫毬蛋白%血清%豬
륜상병독감염%장염%면역구단백%혈청%저
rotavirus infection%enteritis%immunoglobulin%serum%swine
目的: 观察口服猪血清免疫球蛋白治疗轮状病毒肠炎的疗效和安全性. 方法: 研究对象为1998年10月~1999年1月和1999年11月~2000年1月在广州市四家大医院住院或门诊的3岁以下轮状病毒肠炎患儿,病程在2天以内.共观察322例,其中双盲对照试验243例住院患儿(治疗组128例和对照组115例),采用分层分段随机双盲设计,分别予猪血清免疫球蛋白口服液或安慰剂;开放试验(开放组)79例门诊患儿给予猪血清免疫球蛋白口服液.3组的剂量均为 0.5 ml*kg-1 次,每日3次口服,疗程3天.所有患儿均予同样支持治疗,有脱水者给予静脉补液或口服补液纠正水电解质平衡紊乱. 结果: 双盲对照试验治疗组的总有效率(痊愈+显效)和痊愈率分别为 73.5%和 38.3%,均分别显著高于对照组的 51.3%和 14.8%(P<0.01).开放组的疗效与双盲对照试验治疗组相近,总有效率和痊愈率分别为81%和 39.2%,(P>0.05). 结论: 猪血清免疫球蛋白口服液治疗婴幼儿轮状病毒肠炎安全、有效、服用方便, 值得临床推广应用.
目的: 觀察口服豬血清免疫毬蛋白治療輪狀病毒腸炎的療效和安全性. 方法: 研究對象為1998年10月~1999年1月和1999年11月~2000年1月在廣州市四傢大醫院住院或門診的3歲以下輪狀病毒腸炎患兒,病程在2天以內.共觀察322例,其中雙盲對照試驗243例住院患兒(治療組128例和對照組115例),採用分層分段隨機雙盲設計,分彆予豬血清免疫毬蛋白口服液或安慰劑;開放試驗(開放組)79例門診患兒給予豬血清免疫毬蛋白口服液.3組的劑量均為 0.5 ml*kg-1 次,每日3次口服,療程3天.所有患兒均予同樣支持治療,有脫水者給予靜脈補液或口服補液糾正水電解質平衡紊亂. 結果: 雙盲對照試驗治療組的總有效率(痊愈+顯效)和痊愈率分彆為 73.5%和 38.3%,均分彆顯著高于對照組的 51.3%和 14.8%(P<0.01).開放組的療效與雙盲對照試驗治療組相近,總有效率和痊愈率分彆為81%和 39.2%,(P>0.05). 結論: 豬血清免疫毬蛋白口服液治療嬰幼兒輪狀病毒腸炎安全、有效、服用方便, 值得臨床推廣應用.
목적: 관찰구복저혈청면역구단백치료륜상병독장염적료효화안전성. 방법: 연구대상위1998년10월~1999년1월화1999년11월~2000년1월재엄주시사가대의원주원혹문진적3세이하륜상병독장염환인,병정재2천이내.공관찰322례,기중쌍맹대조시험243례주원환인(치료조128례화대조조115례),채용분층분단수궤쌍맹설계,분별여저혈청면역구단백구복액혹안위제;개방시험(개방조)79례문진환인급여저혈청면역구단백구복액.3조적제량균위 0.5 ml*kg-1 차,매일3차구복,료정3천.소유환인균여동양지지치료,유탈수자급여정맥보액혹구복보액규정수전해질평형문란. 결과: 쌍맹대조시험치료조적총유효솔(전유+현효)화전유솔분별위 73.5%화 38.3%,균분별현저고우대조조적 51.3%화 14.8%(P<0.01).개방조적료효여쌍맹대조시험치료조상근,총유효솔화전유솔분별위81%화 39.2%,(P>0.05). 결론: 저혈청면역구단백구복액치료영유인륜상병독장염안전、유효、복용방편, 치득림상추엄응용.
To evaluate efficacy and safety of oral swine serum immunoglobulins in treatment of infantile rotavirus enteritis. METHODS: 322 infants with rotavirus enteritis were randomly divided into three groups: Double-blinded control trial was carried out in 243 inpatients randomly divided into two groups (128 infants received oral swine serum immunoglobulins in the treatment group, 115 infants received placebo in the control group), and 79 outpatients as the open group received oral swine serum immunoglobulins. Every group was received 0.5 ml*kg-1 of oral swine serum immunoglobulins or placebo thrice daily for 3 days. RESTULTS: The total therapeutic effective rate (cure and apparent effect) and curative rate were 73.5% and 38.3% respectively in the treatment group, significantly higher than 51.3% and 14.8% in the control group (P<0.01). The therapeutic effect of the open group was similar to the treatment group. The total therapeutic effective rate and curative rate were 81% and 39.2% respectively (P>0.05). CONCLUSION: The oral administration of swine serum immunoglobulins is effective, safe and convenient in treating rotavirus enteritis of infants.